CAR-T: Historical Perspectives, Manufacturing and Clinical Applications

When:  Oct 19, 2023 from 18:00 to 19:00 (ET)


Elizabeth Lam

CAR-T: Historical Perspectives, Manufacturing and Clinical Applications

Presented by the ISCT SCA Regional Executive Committee


Join our webinar, "CAR-T: Historical Perspectives, Manufacturing, and Clinical Applications," to uncover the revolutionary world of CAR-T cell therapy. Discover the historical journey and core principles that led to this cutting-edge treatment, and explore the intricacies of its manufacturing process. Delve into its diverse clinical applications, showcasing its potential in transforming patient 

Key Learning Objectives: 

This webinar will delve into the revolutionary field of CAR-T cell therapy, exploring its impact in crucial areas such as history and principles, manufacturing processes, and its diverse range of clinical applications.

CAR-T cell therapy has emerged as a groundbreaking immunotherapy, holding immense promise in the treatment of various diseases, particularly hematologic malignancies. Understanding the core principles and historical context of CAR-T therapy is vital in comprehending its evolution and success.

1. History and Principles:
By delving into the historical perspectives of CAR-T cell therapy, we aim to provide participants with a comprehensive understanding of its development and evolution. From the early concepts to the groundbreaking achievements, this segment will showcase the journey of CAR-T therapy and its transformation into a cutting-edge treatment modality.

2. Manufacturing:
The manufacturing process plays a pivotal role in CAR-T therapy, influencing its efficacy and safety. We will highlight the complexities and innovations in CAR-T cell production, emphasizing the importance of quality control and standardization in ensuring the therapeutic success of CAR-T treatments.

3. Clinical Applications:
The clinical applications of CAR-T therapy have expanded rapidly, encompassing a wide range of diseases and patient populations. In this segment, we will explore the latest clinical advancements and successes of CAR-T therapy, discussing its impact on patient outcomes and its potential to revolutionize medical practices.

The importance of this webinar lies in the transformative potential of CAR-T cell therapy and its ability to bring about positive changes in patients' lives. This is exemplified by research studies, which explored the influence of social determinants of health on CAR-T therapy outcomes for young patients with relapsed/refractory B-acute lymphoblastic leukemia (B-ALL)/lymphoma.

This reinforces the need for equitable and accessible healthcare systems, so that vulnerable populations can benefit from the advancements in CAR-T therapy as well in South and central America.


Desiree Kosan, MS, RN, OCN 

CAR-T Cell Collections Manager

Janssen Pharmaceutical Companies of Johnson & Johnson


Andres Caicedo, PhD

ISCT SCA Regional Vice-President Elect

Professor, Universidad San Francisco De Quito, USFQ




David Stronceck, MD 

Director of the Center for Cellular Engineering (CCE) and acting Chief, Department of Transfusion Medicine at the NIH Clinical Center


“CAR-T: Historical perspectives and manufacturing” Understand the principles, history and manufacturing of CAR-T

David Stroncek is the Director of the Center for Cellular Engineering (CCE) and acting Chief, Department of Transfusion Medicine at the NIH Clinical Center. The CCE is a comprehensive facility that develops and manufactures a wide range of cell and gene therapies for early phase clinical trials. The CCE is currently manufacturing chimeric antigen receptor (CAR) T-cells, T-cell receptor (TCR)-engineered T-cells, cancer vaccines, induced pluripotent stem cells (iPSC), retinal pigmented epithelial cells derived from autologous iPSC and genetically modified hematopoietic stems cells. In past the CCE has manufactured dendritic cells, NK cells, virus specific T-cells and mesenchymal stromal cells. The CCE also processes hematopoietic stem cells for transplantation.

Dr. Stroncek’s research is focused on developing new cell therapies, improving the manufacturing of cell therapies, investigating the mechanism of action of cellular therapies and identifying cell therapy potency markers. He has been an author or co-author on more than 410 publications  

Other leadership positions that Dr. Stroncek’s has previously held include: Chief of the Transfusion Services Section of the Department of Transfusion Medicine; Medical Director of the Blood Bank at the University of Minnesota Hospital and Clinics; and Medical Director of the National Marrow Donor Program. 

He received a bachelor’s of science degree in Chemical Engineering and a Medical Degree from the University of Minnesota. He completed residence training in internal medicine and fellowship training in hematology and oncology at the University of Minnesota. 



Renato Luis Guerino Cunha, MD PhD 

Hematology, Hematotherapy and Cellular Therapy

National Leader of Cellular Therapy program

Investigator of Instituto Oncolcinicas


“CAR-T: Clinical applications” Understand clinical applications of CAR-T


Renato Luis Guerino Cunha is a National Leader of Cellular Therapy program and Investigator of Instituto Oncolcinicas in Brazil. He holds a Bachelor of Medicine from the Faculty of Medicine at the Federal University of Uberlândia, specializing in Internal Medicine, in Hematology and Hemotherapyand Bone Marrow Transplantation  at the Hospital das Clínicas da Faculdade de la Universidade de São Paulo in Ribeirão Preto (HC-FMRP-USP). He also holds Doctor of Clinical Medicine from the Faculty of Medicine of Ribeirão Preto, University of São Paulo, and Doctor of Cellular Therapy from the University of Paris-Diderot (Paris VII, Paris-France) with a  Postdoctoral fellowship in Bone Marrow Transplantation and Cellular Therapy at the National Cancer Institute (ETIB-NCI/NHI) in Bethesda, USA.

He was a Professor at the Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), and Coordinator of the Bone Marrow Transplant and Cellular Therapy Unit at HC-FMRP-USP.
He is an associate member of the Brazilian Society of Bone Marrow Transplantation and the Brazilian Association of Hematology and Hemotherapy. Since 2015, he has been a member of the American College of Physicians, and since 2016, a member of the American Society of Hematology. In 2019, he performed the first CAR T-cell therapy for a patient in Brazil and, in 2021, coordinated the Brazilian Consensus on Genetically Modified Cells of the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy.


Online Instructions:
Login: Free access is available for CGT professionals in South and Central America regardless of membership statues. Contact Liz: